Document:

Exhibit
4.35

 

COMMON
STOCK PURCHASE AGREEMENT

 

This
Common Stock Purchase Agreement (this “Agreement”) is made and entered into as of April __, 2020, by and among Aegea
Biotechnologies, Inc., a Delaware corporation (the “Company”), and Tauriga Sciences, Inc., a Delaware corporation
(“Investor”).

 

Whereas,
the Company desires to sell to the Investor, and the Investor desires to purchase from the Company, shares of the Company’s Common
Stock on the terms and conditions set forth in this Agreement;

 

Now,
therefore, the parties hereby agree as follows:

 

1.
AGREEMENT TO PURCHASE AND SELL STOCK.

 

1.1
Agreement to Purchase and Sell. The Company agrees to sell to the Investor at the Closing, and each Investor agrees to purchase
from the Company at the Closing, the number of shares of Common Stock set forth on the Stock Purchase Schedule attached as Exhibit C
to this Agreement (the “Stock Purchase Schedule”), at a price of Four Dollars ($4.00) per share, for a total purchase
price for Investor as shown on the Stock Purhase Schedule (the “Purchase Price”). Such shares may be purchased by
payment by check or wire transfer to a bank account designated by the Company. The shares of Common Stock purchased and sold pursuant
to this Agreement will be hereinafter referred to as the “Purchased Shares”.

 

2.
CLOSING.

 

The
purchase and sale of the Purchased Shares will take place at the offices of Procopio, Cory, Hargreaves & Savitch LLP (“Procopio”),
upon the satisfaction or waiver of all of the conditions to closing set forth in Sections 5 herein (which time and place are hereafter
referred to in this Agreement as the “Closing”), at such time that the parties may agree. At the Closing, or promptly
thereafter, the Investors shall deliver to the Company, the Purchase Price and upon the satisfaction of the conditions to Closing described
herein, the Company will deliver to each Investor a certificate representing the number of Purchased Shares that such Investor has agreed
to purchase hereunder against delivery to the Company the full purchase price of such Purchased Shares, paid by (i) a check payable to
the Company’s order, (ii) wire transfer of funds to the Company, or (iii) any combination of the foregoing.

 

3.
REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

 

The
Company hereby represents and warrants to the Investor that the statements in the following paragraphs of this Section 3 are all true
and correct on and as of the date of this Agreement:

 

3.1
Organization, Good Standing and Qualification. The Company has been duly incorporated and organized, and is validly existing
in good standing, under the laws of the State of Delaware. The Company has the corporate power and authority to enter into and perform
this Agreement, to own and operate its properties and assets, and to carry on its business as currently conducted and as presently proposed
to be conducted.

 

    	 

     

    

 

3.2
Due Authorization. All corporate action on the part of the Company’s directors and stockholders necessary for the authorization,
execution, delivery of, and the performance of all obligations of the Company under this Agreement, the authorization, issuance, reservation
for issuance and delivery of all of the Purchased Shares being sold under this Agreement, will by the Closing have been taken, and this
Agreement constitutes valid and legally binding obligations of the Company, enforceable in accordance with their respective terms, except
as may be limited by (i) applicable bankruptcy, insolvency, reorganization or others laws of general application relating to or affecting
the enforcement of creditors’ rights generally and (ii) the effect of rules of law governing the availability of equitable remedies.

 

3.3
Valid Issuance of Stock. The Purchased Shares, when issued and paid for as provided in this Agreement will be duly authorized
and validly issued, fully paid and nonassessable.

 

3.4
Litigation. There is no action, suit, proceeding, claim, arbitration or investigation (“Action”) pending
(or, to the Company’s knowledge, currently threatened) against the Company, its activities, properties or assets.

 

3.5
Status of Proprietary Assets. To the Company’s knowledge, the Company has full title and ownership of, or is duly licensed
under or otherwise authorized to use, all patents, patent applications, trademarks, service marks, trade names, copyrights, mask works,
trade secrets, confidential and proprietary information, designs and proprietary rights (all of the foregoing collectively hereinafter
referred to as the “Proprietary Assets”), necessary to enable it to carry on its business as now conducted.

 

3.6
Compliance with Law and Documents. The Company is not in violation or default of any provisions of its Certificate of Incorporation
attached hereto as Exhibit A (“Certificate of Incorporation”) or its Bylaws, attached hereto as Exhibit B,
and to the Company’s knowledge, except for any violations that individually and in the aggregate would have no material adverse
impact on the Company’s business, the Company is in compliance with all applicable statutes, laws, and regulations of the United
States of America.

 

4.
REPRESENTATIONS AND WARRANTIES OF INVESTOR.

 

The
Investor hereby represents and warrants to, and agrees with, the Company, as of the date of this Agreement that:

 

4.1
Authorization. This Agreement constitutes such Investor’s valid and legally binding obligation, enforceable in accordance
with its terms except as may be limited by (i) applicable bankruptcy, insolvency, reorganization or other laws of general application
relating to or affecting the enforcement of creditors’ rights generally and (ii) the effect of rules of law governing the availability
of equitable remedies. Each Investor represents that such Investor has full power and authority to enter into this Agreement.

 

4.2
Purchase for Own Account. The Purchased Shares to be purchased by such Investor hereunder will be acquired for investment
for such Investor’s own account, not as a nominee or agent, and not with a view to the public resale or distribution thereof within
the meaning of the 1933 Act, and such Investor has no present intention of selling, granting any participation in, or otherwise distributing
the same. If not an individual, such Investor also represents that such Investor has not been formed for the specific purpose of acquiring
Purchased Shares.

 

    	 

     

    

 

4.3
Disclosure of Information. Such Investor has received or has had full access to all the information he/she/it considers necessary
or appropriate to make an informed investment decision with respect to the Purchased Shares to be purchased by such Investor under this
Agreement. Such Investor further has had an opportunity to ask questions and receive answers from the Company regarding the terms and
conditions of the offering of the Purchased Shares and to obtain additional information (to the extent the Company possessed such information
or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to such Investor or to which
such Investor had access. The foregoing, however, does not in any way limit or modify the representations and warranties made by the
Company in Section 3.

 

4.4
Investment Experience. Such Investor understands that the purchase of the Purchased Shares involves substantial risk. Such
Investor: (i) has experience as an investor in securities of companies in the development stage and acknowledges that such Investor is
able to fend for itself, can bear the economic risk of such Investor’s investment in the Purchased Shares and has such knowledge
and experience in financial or business matters that such Investor is capable of evaluating the merits and risks of this investment in
the Purchased Shares and protecting its own interests in connection with this investment and/or (ii) has a preexisting personal or business
relationship with the Company and certain of its officers, directors or controlling persons of a nature and duration that enables such
Investor to be aware of the character, business acumen and financial circumstances of such persons.

 

4.5
Accredited Investor Status. Investor is an “accredited investor” within the meaning of Regulation D promulgated
under the 1933 Act, or is a non U.S. person under the 1933 Act.

 

4.6
Restricted Securities. Such Investor understands that the Purchased Shares are characterized as “restricted securities”
under the 1933 Act inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under
the 1933 Act and applicable regulations thereunder such securities may be resold without registration under the 1933 Act only in certain
limited circumstances. In this connection, such Investor represents that such Investor is familiar with Rule 144 of the U.S. Securities
and Exchange Commission (the “SEC”), as presently in effect, and understands the resale limitations imposed thereby
and by the 1933 Act. Such Investor understands that the Company is under no obligation to register any of the securities sold hereunder
except as provided herein. Such Investor understands that no public market now exists for any of the Purchased Shares and that it is
uncertain whether a public market will ever exist for the Purchased Shares.

 

4.7
Further Limitations on Disposition. Without in any way limiting the representations set forth above, such Investor further
agrees not to make any disposition of all or any portion of the Purchased Shares unless and until:

 

(a)
there is then in effect a registration statement under the 1933 Act covering such proposed disposition and such disposition is made in
accordance with such registration statement; or

 

    	 

     

    

 

(b)
such Investor shall have notified the Company of the proposed disposition and shall have furnished the Company with a statement of the
circumstances surrounding the proposed disposition, and, at the expense of such Investor or its transferee, with an opinion of counsel,
reasonably satisfactory to the Company, that such disposition will not require registration of such securities under the 1933 Act.

 

Notwithstanding
the provisions of paragraphs (a) and (b) above, no such registration statement or opinion of counsel shall be required: (i) for any transfer
of any Purchased Shares in compliance with SEC Rule 144 or Rule 144A, or (ii) for any transfer of Purchased Shares by an Investor that
is a partnership or a corporation to (A) a partner of such partnership or stockholder of such corporation, (B) a retired partner of such
partnership who retires after the date hereof, (C) the estate of any such partner or stockholder, or (iii) for the transfer by gift,
will or intestate succession by any Investor to his or her spouse or lineal descendants or ancestors or any trust for any of the foregoing;
provided that in each of the foregoing cases the transferee agrees in writing to be subject to the terms of this Section 4 (other than
Section 4.5) to the same extent as if the transferee were an original Investor hereunder.

 

4.8
Legends. It is understood that the certificates evidencing the Purchased Shares will bear the legend set forth below:

 

THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER
THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED
OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM.
THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT
ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

 

The
legend set forth in (a) above shall be removed by the Company from any certificate evidencing Purchased Shares upon delivery to the Company
of an opinion by counsel, reasonably satisfactory to the Company, that a registration statement under the 1933 Act is at that time in
effect with respect to the legended security or that such security can be freely transferred in a public sale without such a registration
statement being in effect and that such transfer will not jeopardize the exemption or exemptions from registration pursuant to which
the Company issued the Purchased Shares.

 

    	 

     

    

 

4.9
Lock-Up Agreement. The Investor agrees that it will not, without the prior written consent of the managing underwriter in
an initial Company IPO, (1) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option
or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any
of the Purchased Shares, or (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of such Purchased Shares, during the one hundred eighty (180) day period following the effective date of the
registration statement for the Company’s IPO (as defined below) (or such other period as may be requested by the Company or an
underwriter, and agreed to by all other stockholders of the Company, to accommodate regulatory restrictions on (a) the publication or
other distribution of research reports and (b) analyst recommendations and opinions, including, but not limited to, the restrictions
contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto.

 

5.
CONDITIONS TO INVESTOR’S OBLIGATIONS AT CLOSING.

 

The
obligations of Investor under Section 2 of this Agreement are subject to the fulfillment or waiver, on or before the Closing, of each
of the following conditions, the waiver of which shall not be effective against any Investor who does not consent to such waiver, which
consent may be given by written, oral or telephone communication:

 

5.1
Representations and Warranties True. Each of the representations and warranties of the Company contained in Section 3 shall
be true and correct on and as of the Closing with the same effect as though such representations and warranties had been made on and
as of the date of the Closing.

 

5.2
Performance. The Company shall have performed and complied with all agreements, obligations and conditions contained in this
Agreement that are required to be performed or complied with by it on or before the Closing and shall have obtained all approvals, consents
and qualifications necessary to complete the purchase and sale described herein.

 

5.3
Securities Exemptions. The offer and sale of the Purchased Shares to the Investors pursuant to this Agreement shall be exempt
from the registration requirements of the 1933 Act, the qualification requirements of the Law and the registration and/or qualification
requirements of all other applicable state securities laws.

 

6.
CONDITIONS TO THE COMPANY’S OBLIGATIONS AT CLOSING.

 

The
obligations of the Company to each Investor under this Agreement are subject to the fulfillment or waiver on or before the Closing of
each of the following conditions by such Investor:

 

6.1
Representations and Warranties. The representations and warranties of such Investor contained in Section 4 shall be true and
correct on the date of the Closings with the same effect as though such representations and warranties had been made on and as of the
Closings.

 

6.2
Payment of Purchase Price. Each Investor shall have delivered to the Company the purchase price in accordance with the provisions
of Section 2.

 

6.3
Securities Exemptions. The offer and sale of the Purchased Shares to the Investors pursuant to this Agreement shall be exempt
from the registration requirements of the 1933 Act, the qualifications requirements of the Law and the registration and/or qualification
requirements of all other applicable state securities laws.

 

    	 

     

    

 

6.4
Proceedings and Documents. All corporate and other proceedings in connection with the transactions contemplated at the Closings
and all documents incident thereto shall be reasonably satisfactory in form and substance to the Company and to the Company’s legal
counsel, and the Company shall have received all such counterpart originals and certified or other copies of such documents as it may
reasonably request.

 

7.
GENERAL PROVISIONS.

 

7.1
Survival of Warranties. The representations, warranties and covenants of the Company and the Investors contained in or made
pursuant to this Agreement shall survive the execution and delivery of this Agreement and the Closings and shall in no way be affected
by any investigation of the subject matter thereof made by or on behalf of any of the Investors, their counsel or the Company, as the
case may be.

 

7.2
Successors and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective
successors and assigns of the parties.

 

7.3
Governing Law. This Agreement shall be governed by and construed under the internal laws of the State of California as applied
to agreements among California residents entered into and to be performed entirely within California, without reference to principles
of conflict of laws or choice of laws.

 

7.4
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument.

 

7.5
Headings. The headings and captions used in this Agreement are used for convenience only and are not to be considered in construing
or interpreting this Agreement. All references in this Agreement to sections, paragraphs, exhibits and schedules shall, unless otherwise
provided, refer to sections and paragraphs hereof and exhibits and schedules attached hereto, all of which exhibits and schedules are
incorporated herein by this reference.

 

Notices.
Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively
given upon personal delivery to the party to be notified or upon deposit with the United States Post Office, by registered or certified
mail, postage prepaid and addressed to the party to be notified at the address indicated for such party on the signature page hereof,
or, in the case of the Company, at 15638 Boulder Mountain Road, Poway California 92064; Attn: President with a copy to Michael J. Kinkelaar,
Esq., Procopio, Cory, Hargreaves & Savitch LLP, 525 B Street, Suite 2200, San Diego, California 92101 or at such other address as
any party or the Company may designate by giving ten (10) days advance written notice to all other parties.

 

7.6
No Finder’s Fees. Each party represents that it neither is nor will be obligated for any finder’s or broker’s
fee or commission in connection with this transaction. Each Investor agrees to indemnify and to hold harmless the Company from any liability
for any commission or compensation in the nature of a finders’ or broker’s fee (and any asserted liability) for which the
Investor or any of its officers, partners, employees, or representatives is responsible.

 

    	 

     

    

 

7.7
Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be
waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the
Company and the Investor. Any amendment or waiver effected in accordance with this Section shall be binding upon each holder of any Purchased
Shares at the time outstanding, each future holder of such securities, and the Company; provided, however, that no condition set forth
in Section 5 may be waived with respect to any Investor who does not consent thereto.

 

7.8
Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision(s)
shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision(s) were so excluded
and shall be enforceable in accordance with its terms.

 

7.9
Entire Agreement. This Agreement, together with all exhibits and schedules hereto, constitutes the entire agreement and understanding
of the parties with respect to the subject matter hereof and supersedes any and all prior negotiations, correspondence, agreements, understandings
duties or obligations between the parties with respect to the subject matter hereof.

 

7.10
Further Assurances. From and after the date of this Agreement, upon the request of any Investor or the Company, the Company
and the Investors shall execute and deliver such instruments, documents or other writings as may be reasonably necessary or desirable
to confirm and carry out and to effectuate fully the intent and purposes of this Agreement.

 

In
Witness Whereof, the parties hereto have executed this Agreement as of the date first above written.

 

	AEGEA
    BIOTECHNOLOGIES, INC.	 	 	 	 
	 	 	 	 	 	 
	By:
    	 	 	 	 	 
	 	Lyle
J. Arnold, Jr, President	 	 	 	 
	 	 	 	 	 	 
	INVESTOR:	 	Amount	Shares	 
	 	 	 	 	 	 
	Tauriga
    Sciences, Inc. 	 	$	 	 
	 	 	 	 	 	 
	By:
    	 	 	 	 	 
	 	Seth
    Shaw, CEO	 	 	 	 
	 	 	 	 	 	 
	Address for Notice:	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

 

    	 

     

    

 

EXHIBIT
A

 

CERTIFICATE
OF INCORPORATION

OF
AEGEA BIOTECHNOLOGIES, INC.

 

[see attached]

 

    	 

     

    

 

EXHIBIT
B

 

Bylaws

 

[see
attached]

 

    	 

     

    

 

EXHIBIT
C

 

Stock
Purchase Schedule

 

	Date
    of Purchase	 	Purchase
    Price	 	Number
    of Shares PurchasedExhibit
4.37

 

SECURITIES
PURCHASE AGREEMENT

This
SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 30, 2021, by and between Tauriga Sciences, Inc.,
a Florida corporation, with headquarters located at 555 Madison Avenue, 5th Floor, New York, NY 10022 (the “Company”), and
GS CAPITAL PARTNERS, LLC, with its address at 30 Washington Street, Suite 5L, Brooklyn, NY 11201 (the “Buyer”).

WHEREAS:

 

A.
The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded
by the rules and regulations as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the
Securities Act of 1933, as amended (the “1933 Act”);

 

B.
Buyer desires to purchase and the Company desires to issue and sell, upon the terms and conditions set forth in this Agreement an 8%
promissory note of the Company, in the form attached hereto as Exhibit A in the aggregate principal amount of $313,000.00 (together with
any note(s) issued in replacement thereof or as a dividend thereon or otherwise with respect thereto in accordance with the terms thereof,
the “Note”), of the Company (the “Common Stock”), upon the terms and subject to the limitations and conditions
set forth in such Note. The Note shall contain a $23,000.00 original issue discount (OID) such that the purchase price for the note shall
be $313,000.00.

 

C.
The Buyer wishes to purchase, upon the terms and conditions stated in this Agreement, such principal amount of Note as is set forth immediately
below its name on the signature pages hereto; and

 

NOW
THEREFORE, the Company and the Buyer severally (and not jointly) hereby agree as follows:

 

1.
Purchase and Sale of Note.

 

a.
Purchase of Note. On the Closing Date (as defined below), the Company shall issue and sell to the Buyer and the Buyer agrees to
purchase from the Company such principal amount of Note as is set forth immediately below the Buyer’s name on the signature pages
hereto.

 

b.
Form of Payment. On the Closing Date (as defined below), (i) the Buyer shall pay the purchase price for the Note to be issued
and sold to it at the Closing (as defined below) (the “Purchase Price”) by wire transfer of immediately available funds to
the Company, in accordance with the Company’s written wiring instructions, against delivery of the Note in the principal amount
equal to the Purchase Price as is set forth immediately below the Buyer’s name on the signature pages hereto, and (ii) the Company
shall deliver such duly executed Note on behalf of the Company, to the Buyer, against delivery of such Purchase Price. 

 

c.
Closing Date. The date and time of the first issuance and sale of the Note pursuant to this Agreement (the “Closing Date”)
shall be on or about April 30, 2021, or such other mutually agreed upon time. The closing of the transactions contemplated by this Agreement
(the “Closing”) shall occur on the Closing Date at such location as may be agreed to by the parties. 

 

    	 

     

    

 

2.
Buyer’s Representations and Warranties. The Buyer represents and warrants to the Company that:

 

a.
Investment Purpose. As of the date hereof, the Buyer is purchasing the Note and the shares of Common Stock issuable upon conversion
of or otherwise pursuant to the Note, such shares of Common Stock being collectively referred to herein as the “Conversion Shares”
and, collectively with the Note, the “Securities”) for its own account and not with a present view towards the public sale
or distribution thereof, except pursuant to sales registered or exempted from registration under the 1933 Act; provided, however,
that by making the representations herein, the Buyer does not agree to hold any of the Securities for any minimum or other specific term
and reserves the right to dispose of the Securities at any time in accordance with or pursuant to a registration statement or an exemption
under the 1933 Act.

 

b.
Accredited Investor Status. The Buyer is an “accredited investor” as that term is defined in Rule 501(a) of Regulation
D (an “Accredited Investor”).

 

c.
Reliance on Exemptions. The Buyer understands that the Securities are being offered and sold to it in reliance upon specific exemptions
from the registration requirements of United States federal and state securities laws and that the Company is relying upon the truth
and accuracy of, and the Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and understandings
of the Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of the Buyer to acquire the
Securities.

 

d.
Information. The Buyer and its advisors, if any, have been, and for so long as the Note remain outstanding will continue to be,
furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and
sale of the Securities which have been requested by the Buyer or its advisors. The Buyer and its advisors, if any, have been, and for
so long as the Note remain outstanding will continue to be, afforded the opportunity to ask questions of the Company. Notwithstanding
the foregoing, the Company has not disclosed to the Buyer any material nonpublic information and will not disclose such information unless
such information is disclosed to the public prior to or promptly following such disclosure to the Buyer. Neither such inquiries nor any
other due diligence investigation conducted by Buyer or any of its advisors or representatives shall modify, amend or affect Buyer’s
right to rely on the Company’s representations and warranties contained in Section 3 below. The Buyer understands that its investment
in the Securities involves a significant degree of risk. The Buyer is not aware of any facts that may constitute a breach of any of the
Company’s representations and warranties made herein.

 

e.
Governmental Review. The Buyer understands that no United States federal or state agency or any other government or governmental
agency has passed upon or made any recommendation or endorsement of the Securities.

 

    	2

     

    

 

f.
Transfer or Re-sale. The Buyer understands that (i) the sale or re-sale of the Securities has not been and is not being registered
under the 1933 Act or any applicable state securities laws, and the Securities may not be transferred unless (a) the Securities are sold
pursuant to an effective registration statement under the 1933 Act, (b) the Buyer shall have delivered to the Company, at the cost of
the Buyer, an opinion of counsel that shall be in form, substance and scope customary for opinions of counsel in comparable transactions
to the effect that the Securities to be sold or transferred may be sold or transferred pursuant to an exemption from such registration,
which opinion shall be accepted by the Company, (c) the Securities are sold or transferred to an “affiliate” (as defined
in Rule 144 promulgated under the 1933 Act (or a successor rule) (“Rule 144”) of the Buyer who agrees to sell or otherwise
transfer the Securities only in accordance with this Section 2(f) and who is an Accredited Investor, (d) the Securities are sold pursuant
to Rule 144, or (e) the Securities are sold pursuant to Regulation S under the 1933 Act (or a successor rule) (“Regulation S”),
and the Buyer shall have delivered to the Company, at the cost of the Buyer, an opinion of counsel that shall be in form, substance and
scope customary for opinions of counsel in corporate transactions, which opinion shall be accepted by the Company; (ii) any sale of such
Securities made in reliance on Rule 144 may be made only in accordance with the terms of said Rule and further, if said Rule is not applicable,
any re-sale of such Securities under circumstances in which the seller (or the person through whom the sale is made) may be deemed to
be an underwriter (as that term is defined in the 1933 Act) may require compliance with some other exemption under the 1933 Act or the
rules and regulations of the SEC thereunder; and (iii) neither the Company nor any other person is under any obligation to register such
Securities under the 1933 Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder (in
each case). Notwithstanding the foregoing or anything else contained herein to the contrary, the Securities may be pledged as collateral
in connection with a bona fide margin account or other lending arrangement. 

 

g.
Legends. The Buyer understands that the Note and, until such time as the Conversion Shares have been registered under the 1933
Act may be sold pursuant to Rule 144 or Regulation S without any restriction as to the number of securities as of a particular date that
can then be immediately sold, the Conversion Shares may bear a restrictive legend in substantially the following form (and a stop-transfer
order may be placed against transfer of the certificates for such Securities):

 

“NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE
HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED
FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE FORM,
THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING
THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED
BY THE SECURITIES.”

 

The
legend set forth above shall be removed and the Company shall issue a certificate without such legend to the holder of any Security upon
which it is stamped, if, unless otherwise required by applicable state securities laws, (a) such Security is registered for sale under
an effective registration statement filed under the 1933 Act or otherwise may be sold pursuant to Rule 144 or Regulation S without any
restriction as to the number of securities as of a particular date that can then be immediately sold, or (b) such holder provides the
Company with an opinion of counsel, in form, substance and scope customary for opinions of counsel in comparable transactions, to the
effect that a public sale or transfer of such Security may be made without registration under the 1933 Act, which opinion shall be accepted
by the Company so that the sale or transfer is effected. The Buyer agrees to sell all Securities, including those represented by a certificate(s)
from which the legend has been removed, in compliance with applicable prospectus delivery requirements, if any. In the event that the
Company does not accept the opinion of counsel provided by the Buyer with respect to the transfer of Securities pursuant to an exemption
from registration, such as Rule 144 or Regulation S, within 2 business days, it will be considered an Event of Default under the Note.

 

    	3

     

    

 

h.
Authorization; Enforcement. This Agreement has been duly and validly authorized. This Agreement has been duly executed and delivered
on behalf of the Buyer, and this Agreement constitutes a valid and binding agreement of the Buyer enforceable in accordance with its
terms.

 

i.
Residency. The Buyer is a resident of the jurisdiction set forth immediately below the Buyer’s name on the signature pages
hereto. 

 

j.
No Short Sales. Buyer/Holder, its successors and assigns, agree that so long as the Note remains outstanding, the Buyer/Holder
shall not enter into or effect “short sales” of the Common Stock or hedging transaction which establishes a short position
with respect to the Common Stock of the Company. The Company acknowledges and agrees that upon delivery of a Conversion Notice by the
Buyer/Holder, the Buyer/Holder immediately owns the shares of Common Stock described in the Conversion Notice and any sale of those shares
issuable under such Conversion Notice would not be considered short sales.

 

3.
Representations and Warranties of the Company. The Company represents and warrants to the Buyer that:

 

a.
Organization and Qualification. The Company and each of its subsidiaries, if any, is a corporation duly organized, validly existing
and in good standing under the laws of the jurisdiction in which it is incorporated, with full power and authority (corporate and other)
to own, lease, use and operate its properties and to carry on its business as and where now owned, leased, used, operated and conducted.

 

b.
Authorization; Enforcement. (i) The Company has all requisite corporate power and authority to enter into and perform this Agreement,
the Note and to consummate the transactions contemplated hereby and thereby and to issue the Securities, in accordance with the terms
hereof and thereof, (ii) the execution and delivery of this Agreement, the Note by the Company and the consummation by it of the transactions
contemplated hereby and thereby (including without limitation, the issuance of the Note and the issuance and reservation for issuance
of the Conversion Shares issuable upon conversion or exercise thereof) have been duly authorized by the Company’s Board of Directors
and no further consent or authorization of the Company, its Board of Directors, or its shareholders is required, (iii) this Agreement
has been duly executed and delivered by the Company by its authorized representative, and such authorized representative is the true
and official representative with authority to sign this Agreement and the other documents executed in connection herewith and bind the
Company accordingly, and (iv) this Agreement constitutes, and upon execution and delivery by the Company of the Note, each of such instruments
will constitute, a legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms.

 

c.
Issuance of Shares. The Conversion Shares are duly authorized and reserved for issuance and, upon conversion of the Note in accordance
with its respective terms, will be validly issued, fully paid and non-assessable, and free from all taxes, liens, claims and encumbrances
with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Company
and will not impose personal liability upon the holder thereof.

 

d.
Acknowledgment of Dilution. The Company understands and acknowledges the potentially dilutive effect to the Common Stock upon
the issuance of the Conversion Shares upon conversion of the Note. The Company further acknowledges that its obligation to issue Conversion
Shares upon conversion of the Note in accordance with this Agreement, the Note is absolute and unconditional regardless of the dilutive
effect that such issuance may have on the ownership interests of other shareholders of the Company.

 

    	4

     

    

 

e.
No Conflicts. The execution, delivery and performance of this Agreement, the Note by the Company and the consummation by the Company
of the transactions contemplated hereby and thereby (including, without limitation, the issuance and reservation for issuance of the
Conversion Shares) will not (i) conflict with or result in a violation of any provision of the Certificate of Incorporation or By-laws,
or (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default (or an event which with notice or
lapse of time or both could become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation
of, any agreement, indenture, patent, patent license or instrument to which the Company or any of its subsidiaries is a party, or (iii)
result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations
and regulations of any self-regulatory organizations to which the Company or its securities are subject) applicable to the Company or
any of its subsidiaries or by which any property or asset of the Company or any of its subsidiaries is bound or affected (except for
such conflicts, defaults, terminations, amendments, accelerations, cancellations and violations as would not, individually or in the
aggregate, have a material adverse effect). All consents, authorizations, orders, filings and registrations which the Company is required
to obtain pursuant to the preceding sentence have been obtained or effected on or prior to the date hereof. The Company is not in violation
of the listing requirements of the OTC marketplace (the “OTC MARKETS”) and does not reasonably anticipate that the Common
Stock will be delisted by the OTC Markets in the foreseeable future, nor are the Company’s securities “chilled” by
DTC. The Company and its subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing. 

 

f.
Absence of Litigation. Except as disclosed in the Company’s public filings, there is no action, suit, claim, proceeding,
inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to
the knowledge of the Company or any of its subsidiaries, threatened against or affecting the Company or any of its subsidiaries, or their
officers or directors in their capacity as such, that could have a material adverse effect. Schedule 3(f) contains a complete list and
summary description of any pending or, to the knowledge of the Company, threatened proceeding against or affecting the Company or any
of its subsidiaries, without regard to whether it would have a material adverse effect. The Company and its subsidiaries are unaware
of any facts or circumstances which might give rise to any of the foregoing.

 

g.
Acknowledgment Regarding Buyer’ Purchase of Securities. The Company acknowledges and agrees that the Buyer is acting solely
in the capacity of arm’s length purchasers with respect to this Agreement and the transactions contemplated hereby. The Company
further acknowledges that the Buyer is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with
respect to this Agreement and the transactions contemplated hereby and any statement made by the Buyer or any of its respective representatives
or agents in connection with this Agreement and the transactions contemplated hereby is not advice or a recommendation and is merely
incidental to the Buyer’ purchase of the Securities. The Company further represents to the Buyer that the Company’s decision
to enter into this Agreement has been based solely on the independent evaluation of the Company and its representatives.

 

h.
No Integrated Offering. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly
or indirectly made any offers or sales in any security or solicited any offers to buy any security under circumstances that would require
registration under the 1933 Act of the issuance of the Securities to the Buyer. The issuance of the Securities to the Buyer will not
be integrated with any other issuance of the Company’s securities (past, current or future) for purposes of any shareholder approval
provisions applicable to the Company or its securities.

 

    	5

     

    

 

i.
Title to Property. The Company and its subsidiaries have good and marketable title in fee simple to all real property and good
and marketable title to all personal property owned by them which is material to the business of the Company and its subsidiaries, in
each case free and clear of all liens, encumbrances and defects except such as are described in Schedule 3(i) or such as would not have
a material adverse effect. Any real property and facilities held under lease by the Company and its subsidiaries are held by them under
valid, subsisting and enforceable leases with such exceptions as would not have a material adverse effect.

 

j.
Bad Actor. No officer or director of the Company would be disqualified under Rule 506(d) of the Securities Act as amended on the
basis of being a “bad actor” as that term is established in the September 19, 2013 Small Entity Compliance Guide published
by the Securities and Exchange Commission.

 

k.
Breach of Representations and Warranties by the Company. If the Company breaches any of the representations or warranties set
forth in this Section 3, and in addition to any other remedies available to the Buyer pursuant to this Agreement, it will be considered
an Event of default under the Note.

 

4.
COVENANTS.

 

a.
Expenses. At the Closing, the Company shall reimburse Buyer for expenses incurred by them in connection with the negotiation,
preparation, execution, delivery and performance of this Agreement and the other agreements to be executed in connection herewith (“Documents”),
including, without limitation, reasonable attorneys’ and consultants’ fees and expenses, transfer agent fees, fees for stock
quotation services, fees relating to any amendments or modifications of the Documents or any consents or waivers of provisions in the
Documents, fees for the preparation of opinions of counsel, escrow fees, and costs of restructuring the transactions contemplated by
the Documents. When possible, the Company must pay these fees directly, otherwise the Company must make immediate payment for reimbursement
to the Buyer for all fees and expenses immediately upon written notice by the Buyer or the submission of an invoice by the Buyer. 

 

b.
Listing. The Company shall promptly secure the listing of the Conversion Shares upon each national securities exchange or automated
quotation system, if any, upon which shares of Common Stock are then listed (subject to official notice of issuance) and, so long as
the Buyer owns any of the Securities, shall maintain, so long as any other shares of Common Stock shall be so listed, such listing of
all Conversion Shares from time to time issuable upon conversion of the Note. The Company will obtain and, so long as the Buyer owns
any of the Securities, maintain the listing and trading of its Common Stock on the OTC MARKETS or any equivalent replacement market,
the Nasdaq stock market (“Nasdaq”), the New York Stock Exchange (“NYSE”), or the American Stock Exchange (“AMEX”)
and will comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of the Financial
Industry Regulatory Authority (“FINRA”) and such exchanges, as applicable. The Company shall promptly provide to the Buyer
copies of any notices it receives from the OTC MARKETS and any other markets on which the Common Stock is then listed regarding the continued
eligibility of the Common Stock for listing on such markets.

 

c.
Corporate Existence. So long as the Buyer beneficially owns any Note, the Company shall maintain its corporate existence and shall
not sell all or substantially all of the Company’s assets, except in the event of a merger or consolidation or sale of all or substantially
all of the Company’s assets, where the surviving or successor entity in such transaction (i) assumes the Company’s obligations
hereunder and under the agreements and instruments entered into in connection herewith and (ii) is a publicly traded corporation whose
Common Stock is listed for trading on the OTC MARKETS, Nasdaq, NYSE or AMEX.

 

    	6

     

    

 

d.
No Integration. The Company shall not make any offers or sales of any security (other than the Securities) under circumstances
that would require registration of the Securities being offered or sold hereunder under the 1933 Act or cause the offering of the Securities
to be integrated with any other offering of securities by the Company for the purpose of any stockholder approval provision applicable
to the Company or its securities.

 

e.
Restricted Shares. The Company shall issue 800,000 of restricted Common Stock to the Buyer as additional consideration for the
purchase of the Note.

 

f.
Breach of Covenants. If the Company breaches any of the covenants set forth in this Section 4, and in addition to any other remedies
available to the Buyer pursuant to this Agreement, it will be considered an event of default under the Note.

 

5.
Governing Law; Miscellaneous.

 

a.
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York without
regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated
by this Agreement shall be brought only in the state courts of New York or in the federal courts located in the state and county of New
York. The parties to this Agreement hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder
and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. The Company and Buyer
waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorney’s fees and
costs. In the event that any provision of this Agreement or any other agreement delivered in connection herewith is invalid or unenforceable
under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith
and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable
under any law shall not affect the validity or enforceability of any other provision of any agreement. Each party hereby irrevocably
waives personal service of process and consents to process being served in any suit, action or proceeding in connection with this Agreement
or any other Transaction Document by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of
delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to
serve process in any other manner permitted by law.

 

b.
Counterparts; Signatures by Facsimile. This Agreement may be executed in one or more counterparts, each of which shall be deemed
an original but all of which shall constitute one and the same agreement and shall become effective when counterparts have been signed
by each party and delivered to the other party. This Agreement, once executed by a party, may be delivered to the other party hereto
by facsimile transmission of a copy of this Agreement bearing the signature of the party so delivering this Agreement.

 

c.
Headings. The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the interpretation
of, this Agreement.

 

d.
Severability. In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule
of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to
conform with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect
the validity or enforceability of any other provision hereof.

 

    	7

     

    

 

e.
Entire Agreement; Amendments. This Agreement and the instruments referenced herein contain the entire understanding of the parties
with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor
the Buyer makes any representation, warranty, covenant or undertaking with respect to such matters. No provision of this Agreement may
be waived or amended other than by an instrument in writing signed by the majority in interest of the Buyer.

 

f.
Notices. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be
in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified,
return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, (iv) via electronic
mail or (v) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party
shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall
be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile
machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice is
to be received) or delivery via electronic mail, or the first business day following such delivery (if delivered other than on a business
day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing
by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur.
The addresses for such communications shall be: 

 

If
to the Company, to:

 

Tauriga
Sciences, Inc.

555
Madison Avenue, 5th Floor

New
York, NY 10022

Attn:
Seth M. Shaw, CEO

 

If to the Buyer:

 

GS
Capital Partners, LLC

30
Washington Street, Suite 5L

Brooklyn,
NY 11201

Attn:
Gabe Sayegh

 

Each
party shall provide notice to the other party of any change in address.

 

g.
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
assigns. Neither the Company nor the Buyer shall assign this Agreement or any rights or obligations hereunder without the prior written
consent of the other. Notwithstanding the foregoing, the Buyer may assign its rights hereunder to any person that purchases Securities
in a private transaction from the Buyer or to any of its “affiliates,” as that term is defined under the 1934 Act, without
the consent of the Company.

 

h.
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

i.
Survival. The representations and warranties of the Company and the agreements and covenants set forth in this Agreement shall
survive the closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of the Buyer. The Company agrees
to indemnify and hold harmless the Buyer and all their officers, directors, employees and agents for loss or damage arising as a result
of or related to any breach or alleged breach by the Company of any of its representations, warranties and covenants set forth in this
Agreement or any of its covenants and obligations under this Agreement, including advancement of expenses as they are incurred.

 

    	8

     

    

 

j.
Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and
shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

k.
No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.

 

l.
Remedies. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Buyer by
vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Company acknowledges that the remedy at law
for a breach of its obligations under this Agreement will be inadequate and agrees, in the event of a breach or threatened breach by
the Company of the provisions of this Agreement, that the Buyer shall be entitled, in addition to all other available remedies at law
or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing or curing any
breach of this Agreement and to enforce specifically the terms and provisions hereof, without the necessity of showing economic loss
and without any bond or other security being required. 

 

IN
WITNESS WHEREOF, the undersigned Buyer and the Company have caused this Agreement to be duly executed as of the date first above written.

 

Tauriga
Sciences, Inc.

 

	By:	 	 
	Name:	Seth
    M. Shaw	 
	Title:	CEO	 

 

GS
CAPITAL PARTNERS, LLC.

 

	By:	 	 
	Name:	Gabe
    Sayegh	 
	Title:	President	 

 

AGGREGATE
SUBSCRIPTION AMOUNT:

 

Aggregate
Principal Amount of Note: $313,000.00

 

Aggregate
Purchase Price:

 

Note
1: $313,000.00 less $23,000.00 in OID

 

    	9

     

    

 

EXHIBIT
A

144
NOTE - $313,000.00

 

    	10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]